Sarina A. Piha‐Paul

Author

Sarina A. Piha‐Paul

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

S Piha-Paul, S. A. PIHA‐PAUL, S. A. Piha-Paul, S. Piha-Paul, S.A. Piha-Paul, Sarina A Piha-Paul, Sarina A. Piha-Paul, Sarina A. Piha‐Paul, Sarina A. Piha‑Paul, Sarina Anne Anne Piha-Paul

1.1K

Publications

31.1K

Citations

H-Index

111

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Merck & Co., Inc., Rahway, NJ, USA (United States)University of California San Diego Institut Gustave Roussy

About

Sarina A. Piha‐Paul is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	120	7.2K
2	Health Sciences	14	15	572
3	Engineering	4	4	591
4	Education	1	1	11
5	Law	1	1	11

Sarina A. Piha‐Paul

266

Publications

29.7K

Citations

H-Index

Page 1

	Year	Citations
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade Mark Ayers, Jared Lunceford, Michael Nebozhyn, Journal of Clinical Investigation	2017	3.7K
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Journal of Clinical Oncology	2019	2.8K
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle, Marwan Fakih, Juanita Lopez, The Lancet Oncology	2020	2.4K
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord, Journal of Clinical Oncology	2019	1K
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, Journal of Clinical Oncology	2018	965
HER kinase inhibition in patients with HER2- and HER3-mutant cancers David M. Hyman, Sarina A. Piha‐Paul, Helen Won, Nature Tumor BiologyOncologyMedicineReceptor Tyrosine KinasePathology	2018	752
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Clinical Cancer Research	2012	528
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil, Journal of Clinical Oncology	2017	522
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno, International Journal of Cancer	2020	485
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer David S. Hong, Razelle Kurzrock, Youngsoo Kim, Science Translational Medicine	2015	428

Page 1